吉利德科学Gilead Sciences（GILD）2025年第四季度及全年业绩报告「NASDAQ」（英文版）（18页）.pdf

1、GILEADSCIENCESANNOUNCESFOURTHQUARTERANDFULLYEAR2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$28.0billion forFullYear2025BiktarvySalesIncreased 7%Year-Over-Yearto$14.3billionforFullYear2025FosterCity,CA,February10,2026-GileadSciences,Inc.(Nasdaq:GILD)announcedtodayitsres

2、ultsofoperationsforthefourthquarterandfullyear2025.“Ourfourthquarterandfull-yearresultscloseoutaverystrongyearforGileadoverall,includingthesuccessfulU.S.launchofYeztugo,theworldsfirsttwice-yearlyHIVpreventiontherapy,andcontinuedgrowthforBiktarvyandDescovy,”saidDanielODay,GileadsChairmanandChiefExecu

3、tiveOfficer.“In2026,ourpotentialnewlaunchesincludetwocancertherapiesandanadditionalHIVtreatmentoption,andwelookforwardtobuildingonthelaunchesofYeztugoandLivdelziforliverdisease.Aswecontinuetoincreaseourpositiveimpactonhealthcare,Gileadiswellpositionedforcontinuedgrowthin2026andbeyond.”FourthQuarter2

4、025FinancialResultsTotalfourthquarter2025revenuesincreased5%to$7.9billioncomparedtothesameperiodin2024,primarilydrivenbyhighersalesofHIVandLiverDiseaseproducts,partiallyoffsetbylowersalesofVeklury(remdesivir).Dilutedearningspershare(“EPS”)was$1.74inthefourthquarter2025comparedto$1.42inthesameperiodi

5、n2024.Theincreasewasprimarilydrivenbyhigherincometaxbenefits,netunrealizedgainsfromequitysecuritiesandhigherproductsales,aswellaslowerselling,generalandadministrative(“SG&A”)expenses.Theincreasewaspartiallyoffsetbyhigheracquiredin-processresearchanddevelopment(“IPR&D”)expensesandanIPR&Dimpairmentcha

6、rgerelatedtoassetsacquiredaspartoftheMYRGmbH(“MYR”)acquisition.Non-GAAPdilutedEPSof$1.86inthefourthquarter2025comparedto$1.90inthesameperiodin2024.ThedecreasewasprimarilydrivenbyhigheracquiredIPR&Dexpenses,partiallyoffsetbyhigherproductsalesandlowerSG&Aexpenses.AsofDecember31,2025,Gileadhad$10.6bill